Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carvedilol for Survival Prediction in ACLF
NCT05180292Unknown
- Sponsor
- Institute of Liver and Biliary Sciences
- Start
- Jan 2022
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of carvedilol in acute-on-chronic liver failure (ACLF), sponsored by Institute of Liver and Biliary Sciences. Primary endpoint: Liver transplant free survival at 28 days. Status: unknown.
02
Drugs
carvedilol
03
Conditions
acute-on-chronic liver failure (ACLF)
Beyond the preview
Go deeper on NCT05180292.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05180292.